Cargando…

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer

INTRODUCTION: Abiraterone acetate and enzalutamide are commonly employed in prostate cancer therapy in an interchangeable manner. These drugs are highly efficacious in androgen antagonism to improve patient outcomes, but they also carry noteworthy risk of adverse effects. Common toxicities vary amon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Yash B., Shaver, Amy L., Kelly, William Kevin, Lu-Yao, Grace
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423609/ https://www.ncbi.nlm.nih.gov/pubmed/36037225 http://dx.doi.org/10.1371/journal.pone.0273826

Ejemplares similares

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
por: Shah, Yash B., et al.
Publicado: (2022)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
por: Izumi, Kouji, et al.
Publicado: (2017)

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial
por: Hara, Isao, et al.
Publicado: (2018)

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
por: Kulkarni, A.A., et al.
Publicado: (2021)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
por: Tsao, Phoebe A., et al.
Publicado: (2023)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018)

Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer
por: Lai, Lillian Y, et al.
Publicado: (2022)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning
por: de Jong, Anouk C., et al.
Publicado: (2023)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
por: Iguchi, Taro, et al.
Publicado: (2019)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
por: Izumi, Kouji, et al.
Publicado: (2022)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2022)

Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study
por: Cone, Eugene B., et al.
Publicado: (2021)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
por: Fang, Mike, et al.
Publicado: (2017)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
por: Sakamoto, Shinichi, et al.
Publicado: (2019)

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer
por: Torquato, Samantha, et al.
Publicado: (2019)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide
por: Serrano Domingo, Juan José, et al.
Publicado: (2021)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2023)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
por: Chung, Jae-Seung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gjtgu1v74f1pkrotbi2c84t84c